FDA record
Cancer
12 drugs, each read from FDA's own review documents and label.
| Drug | Sponsor | First approved | FDA documents |
|---|---|---|---|
| Jideytrozidesamtinib | Nuvalent | July 22, 2026 | 11 |
| Beqalzisonrotoclax | Beone Medicines Usa | May 13, 2026 | 11 |
| Veppanuvepdegestrant | Rigel Pharms | May 1, 2026 | 11 |
| Hernexeoszongertinib | Boehringer Ingelheim | August 8, 2025 | 17 |
| Modeysodordaviprone hydrochloride | Chimerix | August 6, 2025 | 10 |
| Zusdurimitomycin | Urogen Pharma | June 12, 2025 | 10 |
| Emrelistelisotuzumab vedotin-tllv | Abbvie Inc. | May 14, 2025 | 11 |
| Avmapki Fakzynja Co-pack (copackaged)avutometinib potassium; defactinib hydrochloride | Verastem Inc. | May 8, 2025 | 11 |
| Penpulimab-kcqxpenpulimab-kcqx | Akeso Biopharma | April 23, 2025 | 14 |
| Jobevnebevacizumab-nwgd | Biocon Biologics Inc. | April 9, 2025 | 10 |
| Datrowaydatopotamab deruxtecan-dlnk | Daiichi Sankyo Inc. | January 17, 2025 | 13 |
| Opdivo Qvantignivolumab; hyaluronidase-nvhy | Bristol-myers Squibb | December 27, 2024 | 20 |
Being checked before publication: denosumab_bla761392, gemcitabine_nda219683, iberdomide_nda221075, imlunestrant_nda218881, pembrolizumab_berahyaluronidase_bla761467, relacorilant_nda220641, ziftomenib_nda220305.